Cantor Fitzgerald Forecasts Stronger Earnings for SiBone

SiBone (NASDAQ:SIBN) – Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for shares of SiBone in a research note issued on Tuesday, November 11th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.52) per share for the year, up from their previous estimate of ($0.57). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for SiBone’s current full-year earnings is ($0.78) per share. Cantor Fitzgerald also issued estimates for SiBone’s FY2026 earnings at ($0.44) EPS.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The company had revenue of $48.66 million during the quarter, compared to the consensus estimate of $46.67 million. SiBone has set its FY 2025 guidance at EPS.

Several other research firms have also recently weighed in on SIBN. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research report on Wednesday, October 8th. Truist Financial cut their price target on shares of SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Finally, Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.00.

SiBone Stock Down 1.2%

SiBone stock opened at $18.00 on Thursday. The firm has a market cap of $781.02 million, a price-to-earnings ratio of -35.29 and a beta of 0.81. SiBone has a 52-week low of $11.70 and a 52-week high of $20.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 7.97. The firm has a 50 day moving average price of $15.28 and a two-hundred day moving average price of $16.60.

Insider Buying and Selling at SiBone

In related news, SVP Michael A. Pisetsky sold 3,128 shares of SiBone stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $14.25, for a total transaction of $44,574.00. Following the transaction, the senior vice president owned 255,224 shares of the company’s stock, valued at $3,636,942. The trade was a 1.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Anshul Maheshwari sold 3,311 shares of SiBone stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $14.20, for a total transaction of $47,016.20. Following the transaction, the chief financial officer directly owned 211,134 shares in the company, valued at $2,998,102.80. This represents a 1.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 32,009 shares of company stock valued at $485,884. Insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SIBN. ANTIPODES PARTNERS Ltd purchased a new position in shares of SiBone in the 1st quarter worth approximately $34,000. State of Alaska Department of Revenue bought a new stake in SiBone in the 3rd quarter valued at about $39,000. State of Wyoming bought a new stake in SiBone in the 2nd quarter valued at about $55,000. Virtus Advisers LLC purchased a new stake in SiBone during the first quarter valued at about $58,000. Finally, Canada Pension Plan Investment Board bought a new position in SiBone during the second quarter worth about $68,000. 98.11% of the stock is owned by institutional investors.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.